DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Furadantin (Nitrofurantoin) - Warnings and Precautions

 
 



PRECAUTIONS

 

Information for Patients:

Patients should be advised to take Furadantin with food to further enhance tolerance and improve drug absorption.  Patients should be instructed to complete the full course of therapy; however, they should be advised to contact their physician if any unusual symptoms should occur during therapy.
 
Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued.   Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic.  If this occurs, patients should contact their physician as soon as possible. 
 
Patients should be advised not to use antacid preparations containing magnesium trisilicate while taking Furadantin

Carcinogenesis, Mutagenesis, Impairment of Fertility:

Nitrofurantoin was not carcinogenic when fed to female Holtzman rats for 44.5 weeks or to female Sprague-Dawley rats for 75 weeks.  Two chronic rodent bioassays utilizing male and female Sprague-Dawley rats and two chronic bioassays in Swiss mice and in BDF1 mice revealed no evidence of carcinogenicity.
 
Nitrofurantoin presented evidence of carcinogenic activity in female B6C3F1 mice as shown by increased incidences of tubular adenomas, benign mixed tumors, and granulosa cell tumors of the ovary.  In male F344/N rats, there were increased incidences of uncommon kidney tubular cell neoplasms, osteosarcomas of the bone, and neoplasms of the subcutaneous tissue.  In one study involving subcutaneous administration of 75 mg/kg nitrofurantoin to pregnant female mice, lung papillary adenomas of unknown significance were observed in the F1 generation.
 
Nitrofurantoin has been shown to induce point mutations in certain strains of Salmonella typhimurium and forward mutations L5178Y mouse lymphoma cells.  Nitrofurantoin induced increased numbers of sister chromatid exchanges and chromosomal aberrations in Chinese hamster ovary cells but not in human cells in culture.  Results of the sex-linked recessive lethal assay in Drosophila were negative after administration of nitrofurantoin by feeding or by injection.  Nitrofurantoin did not induce heritable mutation in the rodent models examined. 
 
The significance of carcinogenicity and mutagenicity findings relative to the therapeutic use of nitrofurantoin in humans is unknown. 
 
The administration of high doses of nitrofurantoin to rats causes temporary spermatogenic arrest; this is reversible on discontinuing the drug.  Doses of 10 mg/kg/day or greater in healthy human males may, in certain unpredictable instances, produce a slight to moderate spermatogenic arrest with a decrease in sperm count.

Pregnancy:

 

Teratogenic effects:

Pregnancy Category B.  Several reproduction studies have been performed in rabbits and rats at doses up to six times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to nitrofurantoin.  In a single published study conducted in mice at 68 times the human dose (based on mg/kg administered to the dam), growth retardation and a low incidence of minor and common malformations were observed.  However at 25 times the human dose, fetal malformations were not observed; the relevance of these findings to humans is uncertain.  There are, however, no adequate and well-controlled studies in pregnant women.  Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. 

Non-teratogenic effects:

Nitrofurantoin has been shown in one published transplacental carcinogenicity study to induce lung papillary adenomas in the F1 generation mice at doses 19 times the human dose on a mg/kg basis.  The relationship of this finding to potential human carcinogenesis is presently unknown.  Because of the uncertainty regarding the human implications of these animal data, this drug should be used during pregnancy only if clearly needed. 

Labor and Delivery:

See Contraindications.

Nursing Mothers:

Nitrofurantoin has been detected in human breast milk in trace amounts.  Because of the potential for serious adverse reactions from nitrofurantoin in nursing infants under one month of age, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.  (See CONTRAINDICATIONS.)

Pediatric Use:

Safety and effectiveness of Furadantin in neonates below the age of one month have not been established.  (See CONTRAINDICATIONS.)

Page last updated: 2009-02-25

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017